Skip to main content

Table 1 Entry demography of the 41 patients of this study

From: Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone

  

GMA

PSL

Gender:

Male/Female

14/10

7/10

Mean age (range)

 

33.6(15–78)

35.4(13–65)

Extent of UC

Total

17

10

 

Left sided

6

5

 

Recto-sigmoid

1

2

Clinical course

Chronic continuous type

0

1

 

Relapsing remitting type

28

14

 

First UC episode

0

2

Inpatient/Outpatient

 

19/5

17/0

Patients with a history of exposure to PSL

 

17

13

Patients on AZA (50mg/day)

 

8

8

  1. GMA, adsorptive granulocyte and monocyte apheresis; PSL, predonisolone; AZA, azathioprine (started ≥8 weeks ahead of entry).
  2. All patients were included following a relapse of ulcerative colitis (UC)